Viramune(nevirapine)
Nevirapine, Viramune (nevirapine) is a small molecule pharmaceutical. Nevirapine was first approved as Viramune on 1996-06-21. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Nevirapine (discontinued: Nevirapine, Viramune)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nevirapine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VIRAMUNE | Boehringer Ingelheim | N-020636 DISCN | 1996-06-21 | 1 products, RLD |
| VIRAMUNE | Boehringer Ingelheim | N-020933 DISCN | 1998-09-11 | 1 products, RLD |
| VIRAMUNE XR | Boehringer Ingelheim | N-201152 DISCN | 2011-03-25 | 2 products, RLD |
Hide discontinued
Lamivudine
+
Nevirapine
+
Zidovudine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE | Micro Laboratories | N-205626 DISCN | 2018-08-13 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| nevirapine | ANDA | 2024-10-15 |
| nevirapine oral | ANDA | 2012-05-23 |
| viramune | New Drug Application | 2024-10-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv infections | EFO_0000764 | D015658 | B20 |
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
| hepatitis b | — | D006509 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Nevirapine, Viramune Xr, Boehringer Ingelheim | |||
| 8460704 | 2029-03-12 | U-1409 | |
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AG: Non-nucleoside reverse transcriptase inhibitors
— J05AG01: Nevirapine
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR05: Zidovudine, lamivudine and nevirapine
— J05AR07: Stavudine, lamivudine and nevirapine
HCPCS
No data
Clinical
Clinical Trials
235 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | — | — | — | 1 | — | 1 |
| Hiv | D006678 | — | — | — | — | — | 1 | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | 1 | — | 1 |
| Kaposi sarcoma | D012514 | — | C46 | — | — | — | 1 | — | 1 |
| Human herpesvirus 8 | D019288 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nevirapine |
| INN | nevirapine |
| Description | Nevirapine is a dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection. It has a role as an antiviral drug and a HIV-1 reverse transcriptase inhibitor. It is a dipyridodiazepine and a member of cyclopropanes. |
| Classification | Small molecule |
| Drug class | tricyclic compounds; antivirals |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1 |
Identifiers
| PDB | — |
| CAS-ID | 129618-40-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL57 |
| ChEBI ID | 63613 |
| PubChem CID | 4463 |
| DrugBank | DB00238 |
| UNII ID | 99DK7FVK1H (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Nevirapine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,864 documents
View more details
Safety
Black-box Warning
Black-box warning for: Nevirapine, Nevirapine oral, Viramune
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14,086 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use